Research ArticleArticle

Disposition of Ivermectin and Cyclosporin A in CF-1 Mice Deficient in mdr1a P-Glycoprotein

G. Y. Kwei, R. F. Alvaro, Q. Chen, H. J. Jenkins, C. E. A. C. Hop, C. A. Keohane, V. T. Ly, J. R. Strauss, R. W. Wang, Z. Wang, T. R. Pippert and D. R. Umbenhauer
Drug Metabolism and Disposition May 1999, 27 (5) 581-587;

Abstract

The pharmacokinetics and hepatic metabolism of [3H] ivermectin (IVM) and [3H]cyclosporin A (CSA) were investigated in a subpopulation of the CF-1 mouse stock naturally deficient in mdr1a p-glycoprotein (PGP). A survey of key drug-metabolizing activities in liver fractions from PGP-deficient (−/−) or wild-type (+/+) animals indicated the two subpopulations are not different in hepatic metabolic activity and capacity. Intravenous pharmacokinetics of CSA were identical between the two groups, and results from microsomal incubations indicated similar biotransformation of IVM and CSA in liver. Intestinal excretion of [3H]IVM and [3H]CSA was enhanced in PGP (+/+) animals. Absence of PGP resulted in higher blood concentrations of IVM after oral dosing, suggesting enhanced absorption of IVM in (−/−) mice. Concentrations of [3H]IVM and [3H]CSA were always greater in the brains of (−/−) mice compared with (+/+) mice after either i.v. or oral administration. In contrast, liver concentrations of either compound were not different between (+/+) and (−/−) animals after an i.v. dose. These results show the PGP (−/−) and (+/+) subpopulations of CF-1 mice are useful for studying the role of mdr1a PGP in systemic exposure and tissue disposition of PGP substrates in the absence of metabolism differences.

Expression of the mdr1a multidrug resistance efflux transporter p-glycoprotein (PGP)2 in select organs such as the intestinal epithelium, brain capillary endothelium, and placenta plays an important role in systemic, central nervous system, and fetal exposure to a variety of natural toxins and pharmaceuticals. Umbenhauer et al. (1997) recently identified subpopulations of CF-1 mice with varying levels of expression of functional mdr1a PGP, including a population that does not produce PGP [denoted (−/−)]. Animals with wild-type (+/+) or deficient genotypes differ markedly in their sensitivity to the neurotoxicity and teratology induced by abamectin and ivermectin (IVM), two members of the avermectin family of anthelmintics, attributed to differences in accumulation of these compounds in the brain and fetus (Lankas et al., 1997, 1998). Avermectin-sensitive mice were not different from wild-type animals with respect to mdr1b or mdr2, so that functionally all animals were normal in tissues expressing these genes, such as the adrenals (mdr1b) and the liver (mdr2).

The naturally occurring subpopulations of CF-1 PGP-deficient mice are phenotypically similar to the mdr1a and mdr1a/1bknockout strains established by Schinkel et al. (1994). Using the knockout models, Schinkel’s group (Schinkel et al., 1995; Sparreboom et al., 1997) demonstrated differences in pharmacokinetics and tissue distribution, particularly brain accumulation, of several drug substances compared with PGP wild-type mice and elegantly identified the presence of the mdr1a transporter as limiting oral absorption and brain penetration of these drugs. In assessing pharmacokinetics and oral bioavailability of drug substances in new animal models, it is important to determine whether differences in metabolism exist in these populations, as metabolism contributes significantly to disposition of drugs and also because of the significant substrate overlap between PGP and cytochrome P-450 (CYP) 3A (Wacher et al., 1995; Watkins, 1997), a major CYP isozyme in liver and intestine. Furthermore, in certain systems the expression ofmdr1 and CYP3A are coordinately regulated (Schuetz et al., 1996a, b). In this report we characterize the pharmacokinetics and metabolism of xenobiotics in homozygous mdr1a (−/−) and (+/+) CF-1 mice, using two substrates known to be transported bymdr1a PGP, IVM and cyclosporin A (CSA; Saeki et al., 1993). These compounds were each administered by the i.v. and oral routes. Potentially the CF-1 mouse can be an alternative model to the mdr1a knockout strain to study the effect of PGP on drug disposition in target organs.

Materials and Methods

Animals.

Eight-week-old, male CF-1 mice were obtained from Charles River Laboratories (Hollister, CA). Animals were housed in plastic, microisolator cages with wood chip bedding and had ad libitum access to water and Purina Rodent Chow (Purina Mills, Richmond, IN). All procedures were approved by the Merck Research Laboratories Institutional Animal Care and Use Committee. Tail tissue was obtained from all animals and the mice were separated into (+/+), (±), or (−/−) genotypes after PstI RFLP (Umbenhauer et al., 1997). This procedure accurately predicted the “sensitive” or “resistant” phenotype with respect to neurotoxicity induced by avermectins in this mouse strain and the phenotype correlated with the deficiency in PGP protein in these animals. Only the homozygous [(+/+) or (−/−) with respect to mdr1a] animals were used in subsequent experiments.

Chemicals and Dose Preparation.

IVM (mixture of 80% B1a and 20% B1b) and [22,23-3H] IVM B1a were synthesized by Merck Research Laboratories. CSA (Neoral microemulsion solution) was obtained from Sandoz Pharmaceutical Co. (East Hanover, NJ). [mebmt β-3H] CSA was obtained from Amersham Life Science, Inc. (Arlington Heights, IL). 8,9-Z-4′Epi-methylamino-avermectin B1a (MK-244) and 4,4-dimethyl-mebmt-CSA (L-674,184) were used as internal standards in IVM and CSA quantification procedures, respectively.

Due to extreme sensitivity of CF-1 PGP (−/−) mice to abamectin/IVM toxicity, a dose below the LD50 (0.3 mg/kg) for abamectin was selected for IVM administration. IVM and CSA were given at doses expected to not saturate transporter systems. Tritiated IVM B1a was diluted with unlabeled compound to yield a specific activity of 400 μCi/mg; thus only the B1a component was radiolabeled. The i.v. dose, 0.2 mg/kg, was evaporated from a solution in ethanol and reconstituted in mouse serum for administration via the tail vein (approximately 3 μCi/mouse, 0.2 ml/mouse). The oral dose, 0.2 mg/kg, was suspended in 0.5% aqueous methylcellulose.

Tritiated CSA was diluted with the Neoral solution in saline to give a specific activity of 100 μCi/mg. The dose for i.v. and oral administration was 1 mg/kg (approximately 3 μCi/mouse, 0.2 ml/mouse). All animals were dosed in the fasted state. Food was returned to the animals 2 h after dosing. All other chemicals and reagents were of the highest grade commercially available.

Verapamil hydrochloride and [3H]IVM was formulated as above and coadministered i.v. The dose was 1 mg/kg verapamil and 0.2 mg/kg IVM. Blood and tissues were collected as described 2 h postdose.

Study Design and Sample Analysis.

Three to four mice from each group were sacrificed at each time point after oral or i.v. administration. Blood was collected by cardiac puncture and the liver, gall bladder, brain, and small intestines were removed. Lumenal contents were obtained by flushing the small intestine (stomach to caecum) with 5 to 10 ml of saline. All samples, except whole blood, were frozen at −70°C until analysis.

Aqueous homogenates were prepared from liver and brain in a Dounce homogenizer, using a 1:3 or 1:4 tissue/water ratio. A 0.5-ml aliquot was air-dried and total radioactivity in these samples was determined by combustion in a Model 307 sample oxidizer (Packard Instrument Co., Downers Grove, IL), followed by scintillation counting. Total radioactivity in whole blood was determined in the same manner. Gall bladders from three animals in each treatment group at each time point were pooled, diluted to 1 ml in water, and homogenized. Total radioactivity in pooled bile and in intestinal wash was determined by scintillation counting. Results are reported as ng equivalent/ml or nanogram equivalent in the collected fraction, mean ± S.D.,n = 3–4. The 2-h liver, brain, and intestinal wash samples from three to four mice were pooled and extracted twice with ethyl acetate. Radioactivity associated with parent compound in the extract was determined by radiochromatographic analysis using a methanol/water gradient mobile phase on a Zorbax SB-C8 column (DuPont, Wilmington, DE; see below).

Liquid Chromatography-Mass Spectrometry (LC-MS) Analysis.

Blood (0.2 ml) was extracted twice with 4 ml ethyl acetate. The extracts were combined, evaporated under nitrogen, and the residue reconstituted in acetonitrile/water (1:1, v/v). All LC-MS and LC-MS/MS experiments were performed with Perkin-Elmer Sciex API 300 mass spectrometers (Perkin-Elmer Cetus Instruments, Eden Prairie, MN), upgraded to API 365 specifications. All HPLC procedures were performed under isocratic conditions using Keystone NH250 × 4.6 mm columns (5 mm). The mobile phase for quantitation of IVM was 90% acetonitrile + 10% H2O containing 10 mM ammonium acetate. For quantitation of CSA the mobile phase contained an additional 0.1% trifluoroacetic acid. The flow rate was 400 μl/min and 80 μl/min went to the mass spectrometer. The electrospray interface was used for ionization. Full scan MS/MS mass spectra were obtained and the following transitions were monitored: 892.4 → 307.2 (IVM), 886.4 → 158.1 (MK-244), 1219.8 → 1202.8 (CSA), and 1233.8 → 1216.8 (L-674,184). Standard curve samples (range 5–500 ng/ml for IVM and 1–600 ng/ml for CSA) and quality control samples were prepared to allow quantitation and validation of the method. The lower limit of quantification was 5 ng/ml for IVM and 1 ng/ml for CSA. Results are reported as ng/ml blood, means ± S.D.,n = 3–4.

Pharmacokinetic Analysis.

Pharmacokinetic parameters were calculated for CSA after i.v. administration. Area under the blood-concentration time curve (AUC) from 0 to 24 h was determined by the linear trapezoidal rule. Clearance was calculated as the Dosei.v. divided by AUC. The Vdss of CSA was determined as follows: Vdss = Dosei.v. × AUMC(0–24)/AUC2(0–24) and MRT was calculated as AUMC/AUC. Half-life was estimated from the slope of the terminal phase of the log concentration-time points using the 6-, 10-, and 24-h concentrations.

CYP and Enzyme Activity Measurements.

Four samples of liver microsomes were obtained from control, untreated mice, each prepared from three pooled livers. Total CYP content was determined by spectrophotometric analysis following the procedure ofOmura and Sato (1964). The activity of CYP3A was compared in these preparations by monitoring testosterone 6β hydroxylation (Wang et al., 1997) and nifedipine oxidation (Guengerich et al., 1986). Briefly, 0.25 mg/ml of microsomal protein was incubated with 250 μM testosterone or 100 μM nifedipine in phosphate buffer containing an NADPH-regenerating system. The reaction was quenched after 10 min with methanol, centrifuged, and the supernatants were injected directly onto an HPLC column and analyzed following published methods (Wang et al., 1997). The activity of NADPH cytochrome c reductase was measured by recording absorbance at 550 nm for 1 min after addition of microsomes to 0.1 mM NADPH and 0.05 mM cytochrome c in buffer. Cytosolic glutathione-S-transferase activity was determined using 1 mM 1-chloro-2,4-dinitrobenzene as the substrate (Habig et al., 1974). Protein was determined using the BioRad reagent with bovine serum albumin as standard. Statistical analysis was performed using two-tailed Student’s t test. An asterisk (*) denotes statistically different mean values, p < .05.

Concentrations of CYP3A and CYP2B in liver microsomes were determined using enzyme-linked immunosorbent assay (ELISA; Beltz and Burd, 1989) and Western blot analysis. Microsomes (final concentration 3 μg/ml) were incubated in ELISA microplate wells overnight at 4°C. Plates were washed, blocked, and incubated with goat anti-rat CYP2B1 and CYP3A2, or anti-human CYP3A4 serum (Daiichiu Pure Chemicals, Inc., Tokyo, Japan) for 1 h and developed with 3,3′,5,5′-tetramethylbenzidine in aqueous dimethylformamide and H2O2 (9:1). The absorbance at 655 nm was recorded in a Bio-Rad (Bio-Rad Laboratories, Inc., Richmond, CA) plate reader.

For Western blot analysis, mouse liver microsomal proteins were separated on a 10% polyacrylamide gel using a Bio-Rad minigel system. Proteins were transferred to nitrocellulose filter paper, washed, and incubated with goat anti-rat CYP3A2 serum in PBS containing 2% dry milk at 4°C overnight. The paper was washed three times with washing buffer and incubated with affinity-purified rabbit anti-goat IgG (H+L) horseradish peroxidase conjugate. The filter was developed with enhanced chemiluminescence detection system reagents (Amersham life Sciences, Inc.). The relative band intensities were quantified by laser densitometry (Model ARCUS II; AGFA Corp., Orangeburg NY).

In Vitro Metabolism of IVM and CSA.

Microsomal metabolism of [3H]IVM and [3H]CSA was performed using mouse liver microsomal fractions with 10 μM substrate and 2 mg/ml protein. After a 30-min incubation, protein was precipitated with methanol, and authentic standard was added for UV identification and analyzed by HPLC (Shimadzu 10A Series HPLC system). The analysis was performed on a Zorbax SB-C8 column with a methanol/water mobile phase. HPLC conditions were: IVM: 0 to 50 min, 86:14 (methanol/water), 50 to 55 min, 100:0; CSA: 0 to 55 min, 80:20, 55 to 60 min, 100:0. The flow rate was 1.0 ml/min. Radioactivity was determined in one-half-minute fraction collections by scintillation counting. Results are reported as percent parent compound remaining after 30 min.

Results

In Vitro Studies.

Tables 1 and2 summarize some physiological parameters associated with the mouse colony and activities of several drug-metabolizing enzymes in subcellular fractions from the livers of PGP (+/+) and (−/−) animals. Both subpopulations are comparable with respect to adult body weight and liver weight as a percentage of body weight (Table 1). Total liver microsomal and cytosolic protein content, as well as total CYP content, are also statistically indistinguishable. The contents of CYP isozymes CYP3A and CYP2B were not different between the (+/+) and (−/−) animals as determined by both ELISA and immunoblot analysis (Table 2, Fig.1).

View this table:
Table 1

Selected biochemical parameters and activities of hepatic drug-metabolizing enzymes in CF-1 mice

View this table:
Table 2

Pharmacokinetics of CSA in male CF-1 mice

Figure 1
Figure 1

Western immunoblots of PGP (+/+) and (−/−) CF-1 mouse liver microsomes using an antibody recognizing rat CYP3A2.

Microsomal metabolism of testosterone to 6β-hydroxytestosterone and oxidation of nifedipine to its pyridine metabolite were not different between (+/+) and (−/−) animals. In addition, the profiles of other metabolites generated from testosterone biotransformation were qualitatively similar (not shown). The activities of NADPH-cytochrome c reductase and cytosolic glutathioneS-transferase also were not different between the two groups of male mice (Table 2). In female mice, 1.3- to 2-fold higher activities of nifedipine oxidation, NADPH-cytochrome c reductase and glutathione S-transferase were found in (−/−) animals.

The extent of metabolism of IVM and CSA in the presence of liver microsomes was not significantly different between (+/+) and (−/−) mice. In male mouse liver microsomal incubations, 88 to 92% of radioactivity remained as parent IVM after 30 min in both (+/+) and (−/−) groups and 89% and 76% in (+/+) and (−/−) microsomes from female mice, respectively. For CSA, 88 to 90% of radioactivity remained as parent CSA in all groups after 30 min. Radioactivity associated with a more polar peak, eluting about 3 min before parent compound, appeared in all CSA incubation samples. This peak, which was not present in time zero samples, accounted for 11 to 12% of total radioactivity in all groups.

Blood Concentration Profiles.

IVM

None of the animals of either genotype showed signs of neurotoxicity after a single i.v. or oral dose of IVM at 0.2 mg/kg. Blood concentration versus time profiles for total radioactivity and for parent IVM after i.v. or oral administration at 0.2 mg/kg are shown in Fig. 2, A and B, respectively. The profiles of total [3H]IVM after i.v. administration were essentially identical between (+/+) and (−/−) animals; parent concentrations were also similar between groups up to 6 h. Concentrations of total radioactivity were up to 3-fold higher in the blood of (−/−) animals after an oral dose; parent compound concentrations also followed this trend (B). AUC values for parent IVM were not calculated because concentrations were below the lower limit of quantification at 6 or 24 h in some animals.

Figure 2
Figure 2

Concentrations of IVM (parent and total [3H]) in blood of male CF-1 mice after an i.v. (A) or oral (B) dose of 0.2 mg/kg.

CSA.

Blood concentration versus time profiles for [3H]CSA and for parent CSA are shown in Fig.3, A (I.V. dose) and B (oral dose). The AUC, clearance, volume of distribution, and half-life values (Table2) indicate similar pharmacokinetic behavior of CSA in the two groups of mice. Large interanimal variability in concentrations of total radioactivity and parent compound after oral administration of CSA precluded any conclusion relating to differences in blood concentrations between the (+/+) and (−/−) animals. Oral bioavailability values were not calculated because parent CSA concentrations were not quantified past 6 h in the oral dosing protocol.

Figure 3
Figure 3

Concentrations of CSA (parent and total [3H]) in blood of male CF-1 mice after an i.v. (A) or oral (B) dose of 1 mg/kg.

Excretion into Bile and Intestinal Lumen after i.v. Administration.

Total radioactivity recovered in the intestinal lumen of CF-1 mice after i.v. administration of [3H]IVM and [3H]CSA is shown in Fig.4, A and B, respectively. Excretion of total radiolabel was diminished in animals deficient in PGP at every time point compared with PGP (+/+) animals and in addition, excretion of [3H]IVM into intestinal lumen [3.43% and 2.41% of dose, by (+/+) and (−/−) mice, respectively] was 8- to 10-fold greater compared with bile over this period. Radiochromatographic analysis of a pooled sample of intestinal wash showed 13.4% of total extractable radioactivity coeluted with parent IVM in (+/+) mice compared with 5.9% as parent in (−/−) mice. Parent IVM constituted less than 5% of total radioactivity in gall bladder bile from any animal in this study and also in a separate study with bile duct-cannulated anaesthetized mice (not shown).

Figure 4
Figure 4

Intestinal excretion of [3H]IVM (A) and [3H]CSA (B) in male CF-1 mice after an i.v. dose of 0.2 mg/kg (IVM) or 1 mg/kg (CSA).

Results are expressed as ng [3H] equivalents excreted, mean ± S.D., n = 4.

After an i.v. dose of CSA, 11.5% and 3.7% of the administered dose was recovered in intestinal lumenal wash from the (+/+) and (−/−) mice, respectively. Parent CSA constituted 17.5% of total extractable radioactivity in the wash from (+/+) animals, compared with 2.7% in samples from (−/−) mice. Less than 2% of total radioactivity in gall bladder bile coeluted with parent CSA in samples collected from any animal at any time point.

Brain and Liver Concentrations.

IVM

Differences in accumulation of [3H]IVM in the brain, a target tissue for IVM neurotoxicity, was apparent between PGP (+/+) and (−/−) mice at every time point. Concentrations of [3H] were relatively constant over time in (+/+) animals by either route of administration (Fig. 5, solid columns). In contrast, concentrations in brains of PGP (−/−) mice increased with time after an oral dose (Fig. 5A, open columns) and were always higher than concentrations measured in (+/+) mice. At 24 h post oral dose, total radioactivity in brains of (−/−) mice were 141 ng equivalent/g, 70-fold higher compared with wild-type mice (2 ng equivalent/g). Parent IVM constituted 90% and 84% of extractable radioactivity from 2- and 24-h brain homogenates pooled from three to four mice, respectively, from the (−/−) group and recovery of extracted radioactivity was similar among all samples.

Figure 5
Figure 5

[3H]IVM concentrations in brains of PGP (+/+) and (−/−) mice after i.v. (A) or oral (B) dosing at 0.2 mg/kg.

Results are means ± S.D., n = 4.

When the PGP substrate and inhibitor, verapamil, were coadministered i.v. (1 mg/kg) with [3H]IVM to (+/+) mice, brain concentrations of [3H]IVM increased approximately 3-fold at 2 h postdose compared with (+/+) animals given IVM alone, without affecting the blood concentration of IVM (not shown). Extracts from these brain samples showed that coadministration of verapamil did not alter the relative profile of parent IVM and other radioactivity-containing peaks under our radiochromatographic conditions.

In contrast to the brain concentration-time profile, liver concentrations after i.v. administration were similar in (+/+) and (−/−) mice (Fig. 6A). The fraction of total [3H] remaining as parent IVM at 2 h was also similar (54% in (+/+) mice and 51% in (−/−) mice). Concentrations in livers were generally higher and consistent with higher systemic concentrations in (−/−) mice after oral administration (Fig. 6B).

Figure 6
Figure 6

[3H]IVM concentrations in livers of PGP (+/+) and (−/−) mice after i.v. (A) or oral (B) dosing at 0.2 mg/kg.

Results are means ± S.D., n = 4.

CSA.

The lack of PGP at the blood-brain barrier resulted in higher brain concentrations of [3H]CSA after i.v. and oral administration (Fig. 7, A and B, respectively, open columns), similar to the pattern seen after IVM administration. Concentrations of [3H]CSA equivalents were 15-fold and 10-fold greater in (−/−) mice 24 h after i.v. and oral dosing, respectively. At 2 and 24 h postdose, 86% and 83% of the extractable radioactivity in brains of CF-1 (−/−) mice coeluted with parent CSA by HPLC analysis, respectively. Liver [3H] concentrations were similar between groups after i.v. administration at all time points. At 2 h postdose, parent CSA constituted 52% versus 46% of extractable [3H] in the livers of (+/+) and (−/−) mice. After oral administration, mean liver CSA concentrations were higher in (−/−) mice but the data were not statistically different due to large interanimal variability.

Figure 7
Figure 7

[3H]CSA concentrations in brains of PGP (+/+) and (−/−) mice after i.v. (A) or oral (B) dosing at 1 mg/kg.

Results are means ± S.D., n = 4.

Discussion

A survey of several drug-metabolizing enzyme activities, together with results of in vitro metabolism of IVM and CSA, indicated that hepatic metabolic capacity was essentially identical in PGP (+/+) and (−/−) subpopulations of CF-1 mice. Activities and quantities of several CYP isozymes were similar under the normal, non drug-induced state. Because accumulation of both IVM and CSA in brains of PGP-deficient mice could not be explained by the small differences in blood concentrations between the (+/+) and (−/−) mice, we conclude the presence or absence of the efflux protein at the blood-tissue barrier is the key factor resulting in selective tissue accumulation of these PGP substrates. The in vivo consequences of the differences found in in vitro activities in female mice (Table 2) are not known; these differences are under investigation in ongoing in vivo studies.

The blood concentration versus time profiles of IVM and CSA were not different between (+/+) and (−/−) male mice after i.v. administration. Although intestinal efflux of both compounds after i.v. administration was diminished in animals lacking PGP, the extent of drug elimination by this route was not sufficient to markedly affect the pharmacokinetics of IVM or CSA. In contrast with decreased intestinal elimination and enhanced oral absorption of Taxol reported in mdr1a knockout mice (Sparreboom et al., 1997), we cannot unequivocally conclude that oral bioavailabilities of IVM and CSA were enhanced in PGP-deficient CF-1 mice from this study, due to assay sensitivity and limited sampling time points. Higher concentrations of parent (and [3H])IVM and [3H]CSA after oral administration in systemic circulation suggests enhanced net absorption in (−/−) mice. Oral absorption of [3H]IVM is over 60% in mice (Merck & Co., internal report) and absorption of CSA is also reported to be high in preclinical species; however, extensive intestinal and hepatic metabolism contributes to the relatively low and variable bioavailability (Kolars et al., 1991; Wu et al., 1995). The relative contribution of intestinal versus hepatic first pass metabolism for CSA is not known in CF-1 mice and studies are in progress to evaluate intestinal CYP3A activity in these two groups of mice. Other factors to consider in interpretation of results of a compound subject to significant first pass extraction by the intestine include the dose and potential PGP-CYP3A interactions in both liver and intestines. The impact of intestinal PGP on oral bioavailability of drugs may be greatest where poor absorption is the main factor limiting oral bioavailability.

The use of PGP inhibitors (pharmaceutical agents and/or inactive excipients) as a means of enhancing systemic and tissue bioavailability of drugs has been demonstrated in vitro (Chervinsky et al., 1993) and in vivo (Webster et al., 1993; Didier and Loor, 1995; van Asperen et al., 1997) and reversal of multidrug resistance with this strategy was effective in cancer patients treated with the PGP inhibitor PSC 833 (Giaccone et al., 1997). In the present study, coadministration of verapamil with IVM increased the concentrations of IVM in brains of (+/+) mice after an i.v. dose. Because verapamil is also metabolized by CYP3A, experiments are underway to evaluate the pharmacokinetic and metabolic interactions in the presence of multiple PGP/CYP3A substrates. The CF-1 mouse model is thus useful to test the role of this efflux protein in absorption, disposition, metabolism, and elimination of drug candidates. The potential for significant interactions and altered dynamic response, however, argue for further investigations to understand the physiological role of PGP and other efflux transporters.

Acknowledgments

The authors thank Dr. Thomas A. Baillie, Dr. Shuet-hing Lee Chiu and Dr. Anthony Y. H. Lu for their support and discussions during the course of these studies. We also thank the Department of Laboratory Animal Resources at the Rahway facility for the care and maintenance of the mouse colony.

Footnotes

  • Send reprint requests to: Dr. Gloria Y. Kwei, Department of Drug Metabolism, Merck Research Laboratories, RY 80-D100, Rahway, NJ 07065. E-mail: kwei{at}merck.com

  • ↵1 Current affiliation: Department of Safety Assessment, Merck Research Laboratories, West Point, PA.

  • Abbreviations used are::
    PGP
    p-glycoprotein
    IVM
    ivermectin
    CSA
    cyclosporin A
    CYP
    cytochrome P-450
    AUC
    area under the (blood or plasma) concentration-time curve
    LC-MS
    liquid chromatography-mass spectrometry
    ELISA
    enzyme-linked immunosorbent assay
    • Received July 15, 1998.
    • Accepted January 28, 1999.

References

  1. ↵
    1. Beltz BS,
    2. Burd GD
    (1989) Immunocytochemical Techniques: Principles and Practice (Blackwell Scientific Publications, Inc, Malden, MA), p 26.
  2. ↵
    1. Chervinsky DS,
    2. Brecher ML,
    3. Hoelcle MJ
    (1993) Cremophor-EL enhances taxol efficacy in a multi-drug resistant C 1300 neuroblastoma cell line. Anticancer Res 13:93–96.
    OpenUrlPubMed
  3. ↵
    1. Didier AD,
    2. Loor F
    (1995) Decreased biotolerability for ivermectin and cyclosporin A in mice exposed to potent p-glycoprotein inhibitors. Int J Cancer 63:263–267.
    OpenUrlPubMed
  4. ↵
    1. Giaccone G,
    2. Linn SC,
    3. Welink J,
    4. Catimel G,
    5. Stieltjes H,
    6. van der Vijgh WJF,
    7. Eeltink C,
    8. Vermorken JB,
    9. Pinedo HM
    (1997) A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors. Clin Cancer Res 3:2005–2015.
    OpenUrlAbstract
  5. ↵
    1. Guengerich FP,
    2. Martin MV,
    3. Beaune PH,
    4. Kremers P,
    5. Wolff T,
    6. Waxman DJ
    (1986) Characterization of the rat and human microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 261:5051–5060.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Habig WH,
    2. Pabst MJ,
    3. Jakoby WB
    (1974) Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem 249:7130–7139.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Kolars JC,
    2. Awni WM,
    3. Merion RM,
    4. Watkins PB
    (1991) First-pass metabolism of cyclosporin by the gut. Lancet 338:1488–1490.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Lankas GR,
    2. Cartwright ME,
    3. Umbenhauer D
    (1997) P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity. Toxicol Appl Pharmacol 143:357–365.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Lankas GR,
    2. Wise LD,
    3. Cartwright ME,
    4. Pippert T,
    5. Umbenhauer DR
    (1998) Placental P-glycoprotein deficiency enhances susceptibility to chemically-induced birth defects in mice. Reprod Toxicol 12:457–463.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Omura T,
    2. Sato R
    (1964) The carbon monoxide-binding pigment of liver microsomes. J Biol Chem 239:2370–2378.
    OpenUrlFREE Full Text
  11. ↵
    1. Saeki T,
    2. Ueda K,
    3. Tanigawa Y,
    4. Hori R,
    5. Komano T
    (1993) Human p-glycoprotein transports cyclosporin A and FK506. J Biol Chem 268:6077–6080.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Schinkel AH,
    2. Smit JJM,
    3. van Tellingen O,
    4. Beijen JH,
    5. Wagenaar E,
    6. van Deemter L,
    7. Mol CAAM,
    8. ven der Valk MA,
    9. Robanus-Maandag EC,
    10. te Riele HP
    (1994) Disruption of the mouse mdr1a p-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491–502.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Schinkel AH,
    2. Wagenaar E,
    3. van Deemter L,
    4. Mol CAAM,
    5. Borst P
    (1995) Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin and cyclosporin A. J Clin Invest 96:1698–1705.
  14. ↵
    1. Schuetz EG,
    2. Beck WT,
    3. Schuetz JD
    (1996a) Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human carcinoma cells. Mol Pharmacol 49:311–318.
    OpenUrlAbstract
  15. ↵
    1. Schuetz EG,
    2. Schinkel AH,
    3. Relling MV,
    4. Schuetz JD
    (1996b) P-glycoprotein: A major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci USA 93:4001–4005.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Sparreboom A,
    2. van Asperen J,
    3. Mayer U,
    4. Schinkel AH,
    5. Smit JW,
    6. Meijer DKF,
    7. Borst P,
    8. Nooijen WJ,
    9. van Tellingen O
    (1997) Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94:2031–2035.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Umbenhauer DR,
    2. Lankas GR,
    3. Pippert TR,
    4. Wise LD,
    5. Cartwright ME,
    6. Hall SJ,
    7. Beare CM
    (1997) Identification of a p-glycoprotein-deficient subpopulation in the CF-1 mouse strain using a restriction fragment length polymorphism. Toxicol Appl Pharmacol 146:88–94.
    OpenUrlCrossRefPubMed
  18. ↵
    1. van Asperen J,
    2. van Tellingen O,
    3. Sparreboom A,
    4. Schinkel AH,
    5. Borst P,
    6. Nooijen WJ,
    7. Beijen JH
    (1997) Enhanced oral bioavailability of paclitaxel in mice treated with the p-glycoprotein blocker SDZ PSC 833. Br J Cancer 76:1181–1183.
    OpenUrlPubMed
  19. ↵
    1. Wacher VJ,
    2. Wu CY,
    3. Benet LZ
    (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13:129–134.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Wang RW,
    2. Newton DJ,
    3. Scheri TD,
    4. Lu AYH
    (1997) Human cytochrome P450 3A4-catalyzed testosterone 6B-hydroxylation and erythromycin N-demethylation: Competition during catalysis. Drug Metab Dispos 25:502–507.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Watkins PB
    (1997) The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Del Rev 27:161–170.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Webster L,
    2. Linsenmeyer MM,
    3. Morton C,
    4. Bishop J,
    5. Woodcock D
    (1993) Measurement of Cremophor EL following Taxol: Plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype. J Natl Cancer Inst 85:1685–1690.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Wu CY,
    2. Benet LZ,
    3. Hebert MF,
    4. Gupta SK,
    5. Rowland M,
    6. Gomez DY
    (1995) Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine. Clin Pharmacol Ther 58:492–497.
    OpenUrlCrossRefPubMed
View Abstract
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleArticle

Disposition of Ivermectin and Cyclosporin A in CF-1 Mice Deficient in mdr1a P-Glycoprotein

G. Y. Kwei, R. F. Alvaro, Q. Chen, H. J. Jenkins, C. E. A. C. Hop, C. A. Keohane, V. T. Ly, J. R. Strauss, R. W. Wang, Z. Wang, T. R. Pippert and D. R. Umbenhauer
Drug Metabolism and Disposition May 1, 1999, 27 (5) 581-587;
Permalink:
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section